Title :

Community pharmacists' interventions to prevent and screen chronic kidney disease patients

Author(s) :

Belaiche, Stephanie [Auteur]
Mercier, Edwige [Auteur]
Cuny, Damien [Auteur]
Impact de l'environnement chimique sur la santé humaine [IMPECS]
Impact de l'environnement chimique sur la santé humaine [IMPECS]
KAMBIA, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Wierre, Patrick [Auteur]
Bertoux, Elisabeth [Auteur]
Mascaut, Daniel [Auteur]
Azar, Raymond [Auteur]
Bataille, Pierre [Auteur]
Bourdon, Franck [Auteur]
Mac Namara, Evelyne [Auteur]
Maisonneuve, Nathalie [Auteur]
Painchart, Bernard [Auteur]
Vrigneau, Laurence [Auteur]
Noel, Christian [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Decaudin, Bertrand [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Glowacki, Francois-Xavier [Auteur]
Impact de l'environnement chimique sur la santé humaine [IMPECS]
Impact de l'environnement chimique sur la santé humaine [IMPECS]

Journal title :

Nephrologie & Therapeutique

Abbreviated title :

Nephrol. Ther.

Volume number :

13

Pages :

87-92

Publication date :

2017-04-01

ISSN :

1769-7255

Keyword(s) :

Chronic kidney disease
Prevention
Pharmacist intervention

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community ...
Show more >Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists' interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6%) or associated with diabetes (44%). About 70% of the patients had a follow up by a nephrologist and 45% of them were good adherent according to the Morisky-Green self-report. However, approximately 20% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10% of patients with a GFR<60mL/min/1.73m2. The community pharmacists' interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Innovation/évaluation des dispositifs médicaux de perfusion
Immunity, inflammation and fibrsis in auto and allo-reactivity

Submission date :

2019-02-26T17:15:45Z